Advertisement

Reactions Weekly

, Volume 1790, Issue 1, pp 170–170 | Cite as

Natalizumab

Malignancies, hepatotoxicities and progressive multifocal leukoencephalopathy: 10 case reports
Case report
  • 7 Downloads

Reference

  1. Foley J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders 39: Apr 2020. Available from: URL: http://doi.org/10.1016/j.msard.2019.101863 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations